AstraZeneca is a science-led biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.

The company employs more than 800 people in Canada who work to research, develop and market innovative medicines. AstraZeneca Canada was recently designated a global Clinical Hub for oncology and immuno-oncology clinical studies. We are currently leading global oncology clinical studies in lung, head and neck cancer.

We are focused on developing innovative medicines in three core areas: Cardiovascular, Renal and Metabolic diseases (CVRM); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA).

Our bold aspiration is to improve the lives of 200 million patients by 2025. For more information on our medicines and pipeline, please visit www.astrazeneca.ca

Are you ready to boost your knowledge on hyperkalemia (HK) management with the Masters?

Participate in this online self-learning activity to hear a cardiologist and nephrologist expert pair speak to the clinical burden this condition has had on practice and describe the latest evidence-based strategies for correcting hyperkalemia in patients with comorbidities such as chronic kidney disease and heart failure.

Go Back to EM Marketplace

OR

Go Back to Therapeutics